Lisdexamfetamine Dimesylate Patent Expiration

Lisdexamfetamine Dimesylate is Used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Vyvanse on Feb 23, 2007. 17 different companies have introduced drugs containing Lisdexamfetamine Dimesylate.

Lisdexamfetamine Dimesylate Patents

Given below is the list of patents protecting Lisdexamfetamine Dimesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Vyvanse	US7105486 (Pediatric)	Abuse-resistant amphetamine compounds	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7223735 (Pediatric)	Abuse resistant lysine amphetamine compounds	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7655630 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7659253 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7659254 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7662787 (Pediatric)	Abuse resistant lysine amphetamine compounds	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7662788 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7671030 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7671031 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7674774 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7678770 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7678771 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7687466 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7687467 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7700561 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7713936 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7718619 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7723305 (Pediatric)	Abuse-resistant amphetamine prodrugs	Aug 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7105486	Abuse-resistant amphetamine compounds	Jun 29, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7223735	Abuse resistant lysine amphetamine compounds	Jun 29, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7700561	Abuse-resistant amphetamine prodrugs	Jun 29, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7687467	Abuse-resistant amphetamine prodrugs	Apr 08, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7678770	Abuse-resistant amphetamine prodrugs	Mar 25, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7678771	Abuse-resistant amphetamine prodrugs	Mar 25, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7674774	Abuse-resistant amphetamine prodrugs	Mar 18, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7671031	Abuse-resistant amphetamine prodrugs	Feb 28, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7105486	Abuse-resistant amphetamine compounds	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7223735	Abuse resistant lysine amphetamine compounds	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7655630	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7655630	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7659253	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7659253	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7659254	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7662787	Abuse resistant lysine amphetamine compounds	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7662787	Abuse resistant lysine amphetamine compounds	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7662788	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7671030	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7671031	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7674774	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7678770	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7678771	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7687466	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7687467	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7700561	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7713936	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7718619	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa
Vyvanse	US7723305	Abuse-resistant amphetamine prodrugs	Feb 24, 2023 (Expired)	Takeda Pharms Usa

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lisdexamfetamine Dimesylate's patents.

Latest Legal Activities on Lisdexamfetamine Dimesylate's Patents

Given below is the list recent legal activities going on the following patents of Lisdexamfetamine Dimesylate.

Activity	Date	Patent Number

Payment of Maintenance Fee, 12th Year, Large Entity	21 Oct, 2021	US7718619(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	21 Oct, 2021	US7713936
Payment of Maintenance Fee, 12th Year, Large Entity	21 Oct, 2021	US7723305(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	24 Sep, 2021	US7700561(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7674774(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7687466(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7678770(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7671031(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7671030(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	18 Aug, 2021	US7678771(Litigated)

Lisdexamfetamine Dimesylate's Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Lisdexamfetamine Dimesylate Generic API Manufacturers

Several generic applications have been filed for Lisdexamfetamine Dimesylate. The first generic version for Lisdexamfetamine Dimesylate was by Hikma Pharmaceuticals Usa Inc and was approved on Aug 25, 2023. And the latest generic version is by Sandoz Inc and was approved on Jul 26, 2024.

Given below is the list of companies who have filed for Lisdexamfetamine Dimesylate generic, along with the locations of their manufacturing plants worldwide.

1. ACTAVIS ELIZABETH

Actavis Elizabeth Llc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Actavis Elizabeth.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Discontinued	ORAL	N/A	Aug 25, 2023
20MG	capsule	Discontinued	ORAL	N/A	Aug 25, 2023
30MG	capsule	Discontinued	ORAL	N/A	Aug 25, 2023
40MG	capsule	Discontinued	ORAL	N/A	Aug 25, 2023
50MG	capsule	Discontinued	ORAL	N/A	Aug 25, 2023
60MG	capsule	Discontinued	ORAL	N/A	Aug 25, 2023
70MG	capsule	Discontinued	ORAL	N/A	Aug 25, 2023

Manufacturing Plant Locations
^New

Actavis Elizabeth's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Actavis Elizabeth as present at those locations.

Country

City

Firm Name

United States

Elizabeth

Actavis Elizabeth LLC, A Company of Teva

2. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

3. AMNEAL

Amneal Pharmaceuticals Llc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Amneal.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

Manufacturing Plant Locations
^New

Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.

Country

City

Firm Name

United States

Glasgow	Amneal Pharmaceuticals LLC
East Hanover	Amneal Pharmaceuticals LLC
Branchburg	Amneal Pharmaceuticals, LLC
Piscataway	Amneal Pharmaceuticals, LLC
Hauppauge	Amneal Pharmaceuticals of New York, LLC
Paterson	Amneal Pharmaceuticals, Llc
Brookhaven	Amneal Pharmaceuticals of New York, LLC
Bridgewater	Amneal Complex Products Research LLC

India

Tal Bavla, Ahmedabad	Amneal Pharmaceuticals Pvt. Ltd.
Matoda	Amneal Pharmaceuticals Private Ltd.
Hyderabad	Amneal Oncology Private Limited
Ahmedabad	Amneal Pharmaceuticals Private Ltd.

4. APOTEX

Apotex Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Apotex.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

Manufacturing Plant Locations
^New

Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.

Country

City

Firm Name

United States

Weston

Apotex Corp.

Canada

Toronto	Apotex Inc.
North York	Apotex Inc.
Richmond Hill	Apotex Inc.
Etobicoke	Apotex, Inc.
Brantford	Apotex Pharmachem Inc.
Winnipeg	Apotex Fermentation Inc.

India

Bengaluru	Apotex Research Private Limited
Bangalore	Apotex Research Private Limited - Bioequivalence Centre
Bangalore	Apotex Pharmachem India Pvt Ltd.

5. ASCENT PHARMS INC

Ascent Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Ascent Pharms Inc.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
20MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
30MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
40MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
50MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
60MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

6. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Hikma.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
10MG	capsule	Prescription	ORAL	AB	Jan 17, 2024

Manufacturing Plant Locations
^New

Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.

Country

City

Firm Name

United States

Eatontown	Hikma Pharmaceuticals USA, Inc.
Cherry Hill	Hikma Pharmaceuticals USA Inc.
Carlsbad	Hikma Cali Inc. DBA Leucadia Pharmaceuticals
Dayton	Hikma Injectables USA Inc

Portugal

Terrugem Snt

Hikma Farmaceutica, (Portugal) S.A.

Jordan

Amman

Hikma Pharmaceuticals LLC

7. LANNETT CO INC

Lannett Co Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

8. MSN

Msn Laboratories Private Ltd has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Msn.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
50MG	tablet, chewable	Prescription	ORAL	AB	Feb 2, 2024
60MG	tablet, chewable	Prescription	ORAL	AB	Feb 2, 2024
10MG	tablet, chewable	Prescription	ORAL	AB	Feb 2, 2024
20MG	tablet, chewable	Prescription	ORAL	AB	Feb 2, 2024
30MG	tablet, chewable	Prescription	ORAL	AB	Feb 2, 2024
40MG	tablet, chewable	Prescription	ORAL	AB	Feb 2, 2024

Manufacturing Plant Locations
^New

Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.

Country

City

Firm Name

India

Rangareddy District	MSN Laboratories Private Limited
Sangareddy	MSN Pharmachem Private Limited
Yadadri Bhuvanagiri District	MSN Organics Private Limited
Rangareddy District	MSN Laboratories Private Limited (Formulations Division, Unit-II)
Isnapur	MSN Laboratories Private Limited, Unit-II
Sangareddy	MSN Laboratories Private Limited, R&D Center
Sangareddy	MSN Laboratories Private Ltd.
Kamareddy	MSN Life Sciences Private Limited
Medak	MSN LIFE SCIENCES PRIVATE LIMITED
Jinnaram, Sangareddy	MSN Laboratories Private Limited - Formulations Division

United States

Piscataway

MSN PHARMACEUTICALS INC

9. MYLAN

Mylan Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Mylan.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

Manufacturing Plant Locations
^New

Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.

Country

City

Firm Name

United States

Rockford	Mylan Institutional, Inc.
Saint Albans	Mylan Technologies, Inc.
Santa Barbara	Mylandon LLC dba Debbie s Delights Santa Barbara Baking Co.
Morgantown	Mylan Specialty, L.P.
Greensboro	Mylan Pharmaceuticals Inc
Morgantown	MYLAN CONSUMER HEALTHCARE Inc.
San Carlos	Mylan Pharmaceuticals Inc.

India

Hyderabad	Mylan Laboratories Limited
Bangalore	Mylan Laboratories Limited
Hosur	Mylan Laboratories Limited
Sarigam	Mylan Laboratories Limited
Sinnar	Mylan Laboratories Limited
Pithampur, District Dhar	Mylan Laboratories Limited
Aurangabad	Mylan Laboratories Limited (FDF-2)
Anekal Taluk, Bangalore	Mylan Laboratories Limited

Canada

Etobicoke

Mylan Pharmaceuticals ULC

Ireland

Inverin

Mylan Teoranta

10. NORWICH

Norwich Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Norwich.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

Manufacturing Plant Locations
^New

Norwich's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Norwich as present at those locations.

Country

City

Firm Name

United States

Norwich	Norwich Pharmaceuticals, Inc.
Norwich	Norwich Clinical Research Associates Limited
Norwich	Norwich Farm Creamery LLC
Norwich	Norwich Meadows Farm, LLC

11. PRINSTON INC

Prinston Pharmaceutical Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Prinston Inc.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

12. RHODES PHARMS

Rhodes Pharmaceuticals Lp has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Rhodes Pharms.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

13. SANDOZ

Sandoz Inc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Sandoz.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
60MG	capsule	Discontinued	ORAL	N/A	Jul 26, 2024
50MG	capsule	Discontinued	ORAL	N/A	Jul 26, 2024
40MG	capsule	Discontinued	ORAL	N/A	Jul 26, 2024
30MG	capsule	Discontinued	ORAL	N/A	Jul 26, 2024
20MG	capsule	Discontinued	ORAL	N/A	Jul 26, 2024
70MG	capsule	Discontinued	ORAL	N/A	Jul 26, 2024

Manufacturing Plant Locations
^New

Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.

Country

City

Firm Name

Austria

Langkampfen	Sandoz GmbH
Kundl	Sandoz GmbH

United States

Princeton	Sandoz Inc
East Hanover	Sandoz Incorporated

Spain

Les Franqueses Del Valles	Sandoz Industrial Products S.A.
Palafolls	Sandoz Industrial Products, S.A.

India

Navi Mumbai

Sandoz Private Limited

14. SPECGX LLC

Specgx Llc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Specgx Llc.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

Manufacturing Plant Locations
^New

Specgx Llc's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Specgx Llc as present at those locations.

Country

City

Firm Name

United States

Raleigh	SpecGx LLC
Saint Louis	SpecGx LLC
Greenville	SpecGx LLC

15. SUN PHARM INDS INC

Sun Pharmaceutical Industries Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Inc.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
20MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
30MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
40MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
50MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
60MG	capsule	Prescription	ORAL	AB	Aug 25, 2023
70MG	capsule	Prescription	ORAL	AB	Aug 25, 2023

16. TEVA PHARMS

Teva Pharmaceuticals Development Inc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Teva Pharms.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
20MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
30MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
40MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
50MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023
60MG	tablet, chewable	Prescription	ORAL	AB	Aug 25, 2023

Pharsight

Pharsight

Lisdexamfetamine Dimesylate Patent Expiration

Lisdexamfetamine Dimesylate Patents

Latest Legal Activities on Lisdexamfetamine Dimesylate's Patents

Lisdexamfetamine Dimesylate's Family Patents

Explore Our Curated Drug Screens

Lisdexamfetamine Dimesylate Generic API Manufacturers

1. ACTAVIS ELIZABETH

Manufacturing Plant Locations
^New

2. ALKEM LABS LTD

3. AMNEAL

Manufacturing Plant Locations
^New

4. APOTEX

Manufacturing Plant Locations
^New

5. ASCENT PHARMS INC

6. HIKMA

Manufacturing Plant Locations
^New

7. LANNETT CO INC

8. MSN

Manufacturing Plant Locations
^New

9. MYLAN

Manufacturing Plant Locations
^New

10. NORWICH

Manufacturing Plant Locations
^New

11. PRINSTON INC

12. RHODES PHARMS

13. SANDOZ

Manufacturing Plant Locations
^New

14. SPECGX LLC

Manufacturing Plant Locations
^New

15. SUN PHARM INDS INC

16. TEVA PHARMS

Have Questions?

Pharsight

Pharsight

Lisdexamfetamine Dimesylate Patents

Latest Legal Activities on Lisdexamfetamine Dimesylate's Patents

Lisdexamfetamine Dimesylate's Family Patents

Explore Our Curated Drug Screens

Lisdexamfetamine Dimesylate Generic API Manufacturers

1. ACTAVIS ELIZABETH

Manufacturing Plant Locations New

2. ALKEM LABS LTD

3. AMNEAL

Manufacturing Plant Locations New

4. APOTEX

Manufacturing Plant Locations New

5. ASCENT PHARMS INC

6. HIKMA

Manufacturing Plant Locations New

7. LANNETT CO INC

8. MSN

Manufacturing Plant Locations New

9. MYLAN

Manufacturing Plant Locations New

10. NORWICH

Manufacturing Plant Locations New

11. PRINSTON INC

12. RHODES PHARMS

13. SANDOZ

Manufacturing Plant Locations New

14. SPECGX LLC

Manufacturing Plant Locations New

15. SUN PHARM INDS INC

16. TEVA PHARMS

Related content

Have Questions?

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New